Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results January 31, 2025
PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan January 27, 2025
